Sionna Therapeutics
Latest round
- Series C
Last raised
- Mar 2024
Total raised
- $293M
Investors
- 12
About Sionna Therapeutics
Established in 2019, and based in Massachusetts, US, Sionna Therapeutics is a clinical-stage company developing novel small molecule therapies targeting the genetic mutation affecting cystic fibrosis (CF) patients. Rowe Price, and Q Healthcare Holdings, LLC. As of 2024, the company is headed by its CEO Mike Cloonan. Sionna offers a range of innovative small compounds that are intended to fix CFTR protein abnormalities. The TMD1, ICL4, and NBD1 domains are the targets of these compounds and are necessary for CFTR function. The company's therapies aim to offer treatment options for cystic fibrosis (CF) patients. In February 2025, Sionna Therapeutics, Inc.59 million shares at USD 18 per share, within the expected USD 16-18 range, on the Nasdaq Global Select Market under the ticker symbol "SION". Sionna Therapeutics, Inc.59 million shares of common stock as part of the listing., respectively.
Who invested in Sionna Therapeutics
12 investors across 2 rounds
See all investors in Sionna Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Sionna Therapeutics
Who invested in Sionna Therapeutics?
Sionna Therapeutics has 12 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Sionna Therapeutics raised?
Sionna Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Sionna Therapeutics last raise money?
Sionna Therapeutics's most recent round on record is a Series C, in Mar 2024.
What does Sionna Therapeutics do?
Established in 2019, and based in Massachusetts, US, Sionna Therapeutics is a clinical-stage company developing novel small molecule therapies targeting the genetic mutation affecting cystic fibrosis (CF) patients.
Where is Sionna Therapeutics headquartered?
Sionna Therapeutics is headquartered in Waltham, US.
Which VCs invest in companies like Sionna Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Sionna Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Sionna Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.